Skip to main content

Advertisement

Table 1 Pharmacokinetic parameters of VCE-003.2. Pharmacokinetic parameters of VCE-003.2 in plasma following a single intravenous (i.v.) (10 mg/kg) and oral (50 mg/kg) dose in Sprague Dawley rats

From: Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration

Compound Route Cmax (ng/mL) Tmax (h) AUCt ng/mL*h) Bioavailability Brain Concentration (24 h) (ng/mL)
VCE-003.2 IV 83160 0.08 475094.96   93.7 ± 37.7
VCE-003.2 ORAL 20266.67 8 327154.14 13.77% 86.8 ± 34.0